Survey: What Will You Do About Rosiglitazone (Avandia)?

On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.